Lynx Therapeutics Sells Worldwide Rights to Novel Oligo Technology to Geron | GenomeWeb

NEW YORK, March 6 - Lynx Therapeutics on Wednesday said it has sold the worldwide rights to its novel oligonucleotide technology to Geron, the controversial stem-cell-development company, for roughly $2.5 million.

The cash-and-stock deal covers the sale of a family of patents that covers process and compositional matter related to oligos containing N3'-P5' phosphoramidate backbone linkages.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.